SOURCE: Dynavax Technologies

Dynavax Technologies

December 09, 2014 06:00 ET

Dynavax Announces Webcast of R&D Day

BERKELEY, CA--(Marketwired - Dec 9, 2014) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Company will host a live webcast in conjunction with its Research and Development (R&D) Day on Thursday, December 11, 2014 in New York City. This event for institutional investors will focus on Dynavax's leadership in the application of toll-like receptor (TLR) biology, including updates on its Phase 3 investigational adult hepatitis B vaccine, HEPLISAV-B™, clinical programs in cancer and asthma, and advancing preclinical candidates. The webcast of the presentations and Q&A will begin at 8:30 a.m. ET and is scheduled to conclude at 11:00 a.m. ET.

The R&D Day will include presentations by Dynavax senior leadership, including Eddie Gray, Chief Executive Officer; Robert Coffman, Chief Scientific Officer; and Robert Janssen, Chief Medical Officer. They will discuss Dynavax's business and areas of R&D focus and provide a scientific overview of TLR immune modulation and its application to the Company's programs. Detailed updates will also be provided on the status of HEPLISAV-B, Dynavax's investigational adult hepatitis B vaccine and most advanced TLR-based product, and SD-101, its lead clinical-stage candidate in cancer immunotherapy.

Two nationally recognized clinical experts in the field of cancer immunotherapy will join the company presenters:

  • Ronald Levy, M.D., Professor of Medicine and Director of the Lymphoma Program at Stanford University School of Medicine and
  • Antoni Ribas, M.D., Professor of Medicine, David Geffen UCLA School of Medicine and Director, JCCC Tumor Immunology Program

Dr. Levy will discuss the rationale for intratumoral injection of SD-101 and ongoing and planned studies in lymphoma with SD-101, combined with local radiation or an anti-CTLA4 antibody. Dr. Ribas will address the challenges and opportunities of immunotherapy combinations in other tumor types, including the rationale for using intratumoral SD-101 as a synergistic combination with an anti-PD-1 antibody in patients with metastatic melanoma.

A link to the live webcast may be accessed by visiting the "Investors" section of the Dynavax website or reached directly at:

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit

Contact Information

  • Contact:
    Michael Ostrach
    Chief Business and Principal Financial Officer
    Email Contact